Li Zhang, MD
The Second Affiliated Hospital of Air Force Military Medical University · Tang-Du Hospital · Sun Yat-sen University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
44
all conditions, ClinicalTrials.gov
NIH grants tied to them
1
5 more share only the name and are not shown
Trial papers in non-small cell lung cancer
0
PubMed author-name match
Trials
Studies that name Li Zhang, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:38 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07610668 · Clinical Value of Saline Infusion Sonohysterography in the Assessment of Cesarean Scar DefectsTang-Du Hospital · recruiting · Infertility · principal investigator
- N/ANCT07494877 · Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in InfertilityTang-Du Hospital · recruiting · Infertility · principal investigator
- Ph1/Ph2NCT07198321 · A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsGenfleet Therapeutics (Shanghai) Inc. · not yet recruiting · Cancer, PDAC, CRC (Colorectal Cancer) · principal investigator
- Ph1NCT06898255 · A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or CachexiaGenfleet Therapeutics (Shanghai) Inc. · recruiting · Cancer Cachexia · principal investigator
- Ph3NCT06082635 · TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Shenzhen TargetRx Co., Ltd. · active not recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT05955391 · TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Shenzhen TargetRx Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2/Ph3NCT05623267 · Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTSun Yat-sen University · recruiting · Limited Stage Small Cell Lung Cancer · principal investigator
- N/ANCT05583409 · SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLCLi Zhang · unknown · Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph1NCT05441956 · TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Shenzhen TargetRx Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT05195632 · Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerPierre Fabre Medicament · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT05184712 · Phase 3 Clinical Study of AK112 for NSCLC PatientsAkeso · active not recruiting · Non-Squamous Non-small Cell Lung Cancer · principal investigator
- Ph1NCT05028556 · A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid TumorsWuhan YZY Biopharma Co., Ltd. · completed · Metastatic or Locally Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT05016544 · Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerSun Yat-sen University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT05003622 · Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsPierre Fabre Medicament · completed · BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma · principal investigator
- Ph2NCT04992858 · Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping MutationsSunshine Lake Pharma Co., Ltd. · withdrawn · Advanced NSCLC · principal investigator
- Ph2NCT04736823 · A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCAkeso · active not recruiting · NSCLC · study chair
- Ph1/Ph2NCT04647344 · A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerAkeso · completed · Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV · principal investigator
- Ph1NCT04577703 · First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid TumorsSunshine Lake Pharma Co., Ltd. · completed · Advanced Solid Tumors · principal investigator
- Ph2NCT04177875 · Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal CancerTongji Hospital · unknown · Esophagus Cancer · principal investigator
- Ph1/Ph2NCT04172454 · Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsAkeso · completed · Advanced Solid Tumors, Melanoma · principal investigator
- Ph2NCT04085250 · Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapySun Yat-sen University · unknown · Stage III Non-small-cell Lung Cancer · principal investigator
- Ph1/Ph2NCT03758287 · Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeSunshine Lake Pharma Co., Ltd. · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT03707509 · Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal CarcinomaJiangsu HengRui Medicine Co., Ltd. · unknown · Nasopharyngeal Carcinoma · principal investigator
- Ph2NCT03595644 · Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung CancerTongji Hospital · completed · Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03558191 · SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.Jiangsu HengRui Medicine Co., Ltd. · completed · Nasopharyngeal Carcinoma · principal investigator
- Ph1NCT03527251 · Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCSun Yat-sen University · unknown · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT03486587 · A Study Evaluating Bacillus Cereus in the Prevention of Afatinib-associated DiarrheaSun Yat-sen University · terminated · Diarrhea, Treatment Side Effects · principal investigator
- Ph2NCT03215693 · X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibBetta Pharmaceuticals Co., Ltd. · unknown · Non-Small Cell Lung Cancer · study chair
- Ph4NCT03081845 · A1 Versus A2® Milk on the Gastrointestinal Physiology, Symptoms and Cognitive Behaviour for the Preschool Childrena2 Milk Company Ltd. · completed · Gut Inflammation · study director
- N/ANCT03049579 · Immune System Stimulation by Probiotic Food SupplementationHangzhou Wei Chuan Foods Co., Ltd. · completed · Flu Symptom · study director
- Ph1NCT02959619 · Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKBetta Pharmaceuticals Co., Ltd. · completed · Solid Tumor, Non-Small Cell Lung Cancer Metastatic · study chair
- Ph2NCT02250599 · Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal CarcinomaSun Yat-sen University · unknown · Nasopharyngeal Neoplasms · principal investigator
- Ph1/Ph2NCT01735409 · Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal CarcinomaSun Yat-sen University · unknown · Nasopharyngeal Neoplasms · principal investigator
- Ph2NCT01533727 · CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)Sun Yat-sen University · withdrawn · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT01531790 · A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer PatientsJiangsu Simcere Pharmaceutical Co., Ltd. · completed · Non-Small Cell Lung Cancer · principal investigator
- Ph2/Ph3NCT01528488 · Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLCSun Yat-sen University · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT01287962 · Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung CancerSun Yat-sen University · unknown · Non-small Cell Lung Cancer · study chair
- Ph2NCT01194453 · Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung CancerSun Yat-sen University · completed · Non-small Cell Lung Cancer, Efficacy · study chair
- Ph2NCT01017679 · Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mgSun Yat-sen University · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00816868 · A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of LungSun Yat-sen University · completed · Non-small Cell Lung Cancer · study chair
- Ph4NCT00762346 · Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone MetastasisSun Yat-sen University · completed · Non Small Cell Lung Cancer, Bone Metastases, High NTX Level · principal investigator
- Ph2NCT00747799 · Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)Sun Yat-sen University · completed · Nasopharyngeal Neoplasms · principal investigator
- Ph3NCT00615667 · Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)Sun Yat-sen University · completed · Kidney Diseases, Nephrotic Syndrome, Tacrolimus · principal investigator
- Ph3NCT00615173 · Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus NephritisSun Yat-sen University · completed · Kidney Diseases, Lupus Nephritis, Tacrolimus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CENTERS FOR DISEASE CONTROL AND PREVENTION, TUBERCULOSIS ELIMINATION, LABORATORYU52PS900454 · NCHHSTP · SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH · fiscal years 2013 to 2014 · $797,940 awarded in 2014Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.